EPS for Inovio Pharmaceuticals, Inc. (INO) Expected At $-0.29; Manufacturers Life Insurance Company The Increased Cullen Frost Bankers (CFR) Position By $620,588

February 22, 2018 - By Peter Erickson

Analysts expect Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report $-0.29 EPS on March, 21.They anticipate $0.07 EPS change or 19.44% from last quarter’s $-0.36 EPS. After having $-0.40 EPS previously, Inovio Pharmaceuticals, Inc.’s analysts see -27.50% EPS growth. The stock increased 0.24% or $0.01 during the last trading session, reaching $4.23. About 58,378 shares traded. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has declined 29.01% since February 22, 2017 and is downtrending. It has underperformed by 45.71% the S&P500.

Manufacturers Life Insurance Company The increased Cullen Frost Bankers Inc (CFR) stake by 0.67% reported in 2017Q3 SEC filing. Manufacturers Life Insurance Company The acquired 6,602 shares as Cullen Frost Bankers Inc (CFR)’s stock declined 3.20%. The Manufacturers Life Insurance Company The holds 990,600 shares with $94.03 million value, up from 983,998 last quarter. Cullen Frost Bankers Inc now has $6.75B valuation. The stock decreased 0.70% or $0.75 during the last trading session, reaching $106.01. About 45,031 shares traded. Cullen/Frost Bankers, Inc. (NYSE:CFR) has risen 44.85% since February 22, 2017 and is uptrending. It has outperformed by 28.15% the S&P500.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $381.95 million. The Company’s SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals had 38 analyst reports since August 10, 2015 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Friday, July 7 report. The rating was maintained by H.C. Wainwright on Thursday, June 8 with “Buy”. On Thursday, June 8 the stock rating was maintained by Aegis Capital with “Buy”. Maxim Group maintained the shares of INO in report on Thursday, June 1 with “Buy” rating. Citigroup initiated the stock with “Buy” rating in Friday, October 6 report. The firm earned “Hold” rating on Wednesday, August 12 by Zacks. As per Friday, September 22, the company rating was maintained by H.C. Wainwright. The firm earned “Buy” rating on Tuesday, August 8 by Stifel Nicolaus. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has “Buy” rating given on Tuesday, November 28 by H.C. Wainwright. The firm has “Buy” rating by Stifel Nicolaus given on Monday, June 26.

Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.17, from 1.31 in 2017Q2. It dropped, as 38 investors sold CFR shares while 78 reduced holdings. 32 funds opened positions while 100 raised stakes. 50.53 million shares or 1.55% less from 51.33 million shares in 2017Q2 were reported. Advantus Capital Mngmt stated it has 0.02% in Cullen/Frost Bankers, Inc. (NYSE:CFR). Old Mutual Customised Solutions (Proprietary) Ltd owns 1,500 shares. Barclays Plc holds 0% of its portfolio in Cullen/Frost Bankers, Inc. (NYSE:CFR) for 9,385 shares. Financial Ser invested in 17 shares or 0% of the stock. The Maryland-based Brown Advisory has invested 0% in Cullen/Frost Bankers, Inc. (NYSE:CFR). Winfield Assoc invested in 0% or 40 shares. Tributary Capital Limited Company has invested 0.01% in Cullen/Frost Bankers, Inc. (NYSE:CFR). Beacon Grp reported 1.57% stake. Bartlett & Llc invested in 110,953 shares or 0.44% of the stock. 38 were reported by Reilly Fin Lc. Rowland And Com Inv Counsel Adv reported 51,510 shares. Principal Inc reported 1.84 million shares or 0.17% of all its holdings. Moreover, Bokf Na has 0.05% invested in Cullen/Frost Bankers, Inc. (NYSE:CFR). Louisiana State Employees Retirement System reported 0.07% of its portfolio in Cullen/Frost Bankers, Inc. (NYSE:CFR). The Illinois-based Trust Department Mb State Bank N A has invested 0% in Cullen/Frost Bankers, Inc. (NYSE:CFR).

Manufacturers Life Insurance Company The decreased Omnicom Group Inc (NYSE:OMC) stake by 38,178 shares to 224,490 valued at $16.63 million in 2017Q3. It also reduced Integer Hldgs Corp stake by 365,345 shares and now owns 23,405 shares. Ishares Inc (EWY) was reduced too.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>